Drug Profile
Progesterone sustained release - Catalent/Dare Bioscience
Alternative Names: DARE-FRT1; DARE-PTB1; Estrogen/progesterone intravaginal - Dare Bioscience/Juniper Pharmaceuticals; JNP 0301; Progesterone intravaginal - Dare Bioscience/Juniper PharmaceuticalsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Juniper Pharmaceuticals
- Developer Dare Bioscience
- Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pregnancy
- No development reported Preterm labour
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Preterm-labour in USA (Vaginal, Ring)
- 30 Mar 2021 Dare Bioscience plans a phase I trial of DARE FRT1 for Preterm labour (Prevention) (Vaginal) in 2022
- 27 Mar 2020 Preclinical development in Preterm-labour was ongoing in USA (Vaginal, Ring)